By Fineline Cube 
Guangzhou-based Bio-Thera Solutions Ltd. (SHA: 688177) announced on September 15, 2025, that it has entered into a licensing and commercialization agreement with Jamjoom Pharma for BAT2306, a biosimilar referencing Cosentyx (secukinumab), targeting the Middle East and North Africa (MENA) markets.
Agreement Details
Under the agreement, Jamjoom Pharma will hold exclusive rights for the distribution and sale of BAT2306 in the MENA region. Jamjoom will manage product registration, market access, and commercialization, while Bio-Thera will oversee research, development, manufacturing, and commercial supply.
BAT2306 Biosimilar Profile
BAT2306 is a human monoclonal antibody (IgG1κ) targeting interleukin-17A (IL-17A). It selectively binds to and neutralizes IL-17A, preventing its interaction with receptors and inhibiting the release of pro-inflammatory cytokines and chemokines. This mechanism is crucial for treating various autoimmune conditions.
Regulatory and Market Expansion
The marketing authorization application (MAA) for BAT2306 has been accepted by China’s National Medical Products Administration (NMPA). Bio-Thera is also preparing to submit applications to the U.S. FDA and the European Medicines Agency (EMA).-Fineline Info & Tech